AbbVie had promising double-digit growth in Skyrizi/Rinvoq and excellent ex-Humira portfolio sales growth. Read why ABBV ...

The European Medicines Agency said on Tuesday that it has withdrawn the marketing authorisation for Abbvie's hepatitis C drug ...

Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, ...

AbbVie's drug met the main goal in a late-stage trial when tested in patients with early Parkinson's disease, the company ...

The insurers are looking to disrupt Big Pharma's model of distributing drugs. One is even offering Humira biosimilars to ...

AbbVie ABBV has outperformed the market over the past 10 years by 1.46% on an annualized basis producing an average annual ...

Epkinly showed an overall response rate of 82% with 62.5% of patients achieving complete response. 65% of patients had grade 1-2 cytokine release syndrome (CRS), though severe cases (grade 3) were ...

AbbVie plans to share results from another phase 3 trial of tavapadon later this year, the pharma said in the release. That ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other best inexpensive stocks to invest in now. The recent market surge has raised concerns about ...

AbbVie reported Thursday that its experimental Parkinson’s drug that it got from Cerevel Therapeutics helped alleviate ...

AbbVie faces growth challenges with mixed Q2 results. Click here for a full investment analysis of ABBV stock.

Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...